Persistence of Weekly Injectable Semaglutide Use in Patients with Diabetes Mellitus and Obesity: A Retrospective Follow-Up in Colombia
Open accessThe DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Semaglutide is an effective antidiabetic agent that is injected weekly to induce weight reduction, and the impact on cardiovascular outcomes is favorable. OBJECTIVE: The aim was to evaluate the persistence of the use of weekly injectable semaglutide in Colombia for 12 months among new users. METHODS: A retrospective longitudinal follow-up study of a cohort of patients with a new prescription of weekly injectable semaglutide between January and December 2022 and persistence for 365 days was evaluated. Kaplan‒Meier survival analyses were performed to evaluate the survival effect of semaglutide. RESULTS: In total, 9356 new users of semaglutide were identified. The average age of the users was 61.6 ± 12.9 years, the main diagnoses were type 2 diabetes mellitus (43.8%) and obesity (41.8%), and 90.8% of them received the 0.25/0.5-mg dose. The mean duration of use was 93.7 ± 76.3 days, but only 13.8% and 0.2% of patients continued the treatment at 6 and 12 months of follow-up, respectively. In total, 35.4% had a prescription for a single month. The other concomitant antidiabetic drugs used were metformin (43.5%), sodium glucose-2 cotransporter inhibitors (38.3%) and insulin (18.2%). CONCLUSIONS: Most of the patients started semaglutide at the suggested doses to continue with staging; however, the persistence of use was low, which may be related to difficulties in access, education on application methods, drug tolerability, and lack of follow-up by the clinician.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“| Colombia (nationwide registers) [49] | Mixed | 35.4% discontinuation after one month of therapy | 13.8% at 6 months; 0.2% at 12 months | Limited access; prohibitive out-of-pocket costs; insufficient clinical follow-up |”
From Adherence and Persistence with GLP-1-Based Therapies: International Real-World Evidence and the Role of Nutritional and Lifestyle Support—A Narrative Review (2026) · cites this paper as [49]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“persistence fell from 35.4% at one month to 13.8% at six months and 0.2% at twelve months—a trajectory consistent with progressive financial exhaustion rather than therapeutic failure per se [49].”
From Adherence and Persistence with GLP-1-Based Therapies: International Real-World Evidence and the Role of Nutritional and Lifestyle Support—A Narrative Review (2026) · cites this paper as [49]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“A 2025 retrospective study of 9356 new semaglutide users in Colombia documented a rapid decline in the persistence curve. Despite over 90% of patients initiating therapy at the recommended starting doses, 35.4% abandoned treatment after a single month, with a mean duration of use of only 93.7 days. By six months, persistence had fallen to 13.8%, and at 12 months, only 0.2% of the cohort remained”
From Adherence and Persistence with GLP-1-Based Therapies: International Real-World Evidence and the Role of Nutritional and Lifestyle Support—A Narrative Review (2026) · cites this paper as [49]
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“In the Colombian semaglutide cohort, where mean out-of-pocket expenditure exceeded USD 300 per month and most patients lacked supplementary private insurance coverage”
From Adherence and Persistence with GLP-1-Based Therapies: International Real-World Evidence and the Role of Nutritional and Lifestyle Support—A Narrative Review (2026) · cites this paper as [49]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
Marso, S. P., Daniels, G. H., Brown-Frandsen, K., Kristensen, P., Mann, J. F. E., Nauck, M. A., Nissen, S. E., Pocock, S., Poulter, N. R., Ravn, L. S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1603827 · Cited by 7,629 · cited 2×
“In addition to adequate comprehensive management of cardiovascular risk, these drugs mitigate potential disease complications, improve quality of life, and decrease mortality [4–7].”
Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Marso, S. P., Bain, S. C., Consoli, A., Eliaschewitz, F. G., Jódar, E., Leiter, L. A., Lingvay, I., Rosenstock, J., Seufert, J., Warren, M. L., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1607141 · Cited by 6,900 · cited 2×
“…in the SUSTAIN-6 study, semaglutide significantly reduced the incidence of the main outcome, namely, MACE, and this was accompanied by a lower frequency of adverse effects than that in the placebo group but a higher probability of discontinuation of therapy due to gastrointestinal problems [6].”
Once-Weekly Semaglutide in Adults with Overweight or Obesity
Wilding, J. P. H., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., McGowan, B. M., Rosenstock, J., Tran, M. T. D., Wadden, T. A., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2032183 · Cited by 5,205 · cited 2×
“…without T2DM was shown to be highly effective in achieving weight reduction compared with the placebo (−12.7 kg) after a follow-up of 68 weeks [9], although the probability of discontinuation of therapy was higher than that with the placebo due to gastrointestinal events (in up to 50% of…”
InfluentialChatterjee, S., Khunti, K., & Davies, M. J. (2017) · The Lancet · doi:10.1016/s0140-6736(17)30058-2 · Cited by 2,577 · cited 2×
“In addition to adequate comprehensive management of cardiovascular risk, these drugs mitigate potential disease complications, improve quality of life, and decrease mortality [4–7].”
Prevalence of and Trends in Diabetes Among Adults in the United States, 1988-2012
Menke, A., Casagrande, S., Geiss, L., & Cowie, C. C. (2015) · JAMA · doi:10.1001/jama.2015.10029 · Cited by 2,362
GLP-1 receptor agonists in the treatment of type 2 diabetes - state-of-the-art
Nauck, M. A., Quast, D. R., Wefers, J., & Meier, J. J. (2021) · Molecular Metabolism · doi:10.1016/j.molmet.2020.101102 · Cited by 1,647 · cited 1×
“In addition, they inhibit glucagon secretion and have other systemic effects, such as changes in intestinal transit and gastric emptying, as well as effects on the central nervous system, altering the sensation of satiety and appetite [8].”
9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes—2023
ElSayed, N. A., Aleppo, G., Aroda, V. R., Bannuru, R. R., Brown, F. M., Bruemmer, D., Collins, B. S., Hilliard, M. E., Isaacs, D., Johnson, E. L., et al. (2023) · Diabetes Care · doi:10.2337/dc23-s009 · Cited by 851 · cited 2×
“Notably, fewer than half of the patients received metformin, both in those with a primary diagnosis of T2DM and those with obesity, which may be consistent with current recommendations for first-line antidiabetic therapy in certain groups of patients [17].”
O'Neil, P. M., Birkenfeld, A. L., McGowan, B., Mosenzon, O., Pedersen, S. D., Wharton, S., Carson, C. G., Jepsen, C. H., Kabisch, M., & Wilding, J. P. H. (2018) · The Lancet · doi:10.1016/s0140-6736(18)31773-2 · Cited by 814 · cited 1×
“The limited persistence of use can also be associated with access difficulties, delays in the approval of treatment by insurers, or ignorance, fear, or lack of training regarding the correct subcutaneous application of the drug [26, 27].”
Sorli, C., Harashima, S.-I., Tsoukas, G. M., Unger, J., Karsbøl, J. D., Hansen, T., & Bain, S. C. (2017) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(17)30013-x · Cited by 745 · cited 1×
“The limited persistence of use can also be associated with access difficulties, delays in the approval of treatment by insurers, or ignorance, fear, or lack of training regarding the correct subcutaneous application of the drug [26, 27].”
Type-2 diabetes mellitus and cardiovascular disease
Henning, R. J. (2018) · Future Cardiology · doi:10.2217/fca-2018-0045 · Cited by 398 · cited 1×
“The management of T2DM involves nonpharmacological strategies related to changes in lifestyle, which promote a healthy diet, aerobic exercise, and the avoidance of tobacco consumption [4, 5].”
Cited by
Dziewierz, A., & Siudak, Z. (2026) · Nutrients · doi:10.3390/nu18111761 · Cited by 3
Brisson, J., Castro-Arteaga, M., Logie, C. H., & Perez‐Brumer, A. (2026) · Social Science & Medicine · doi:10.1016/j.socscimed.2026.119357 · Cited by 2
Metadata
- Authors
- Machado-Duque, M. E., Gaviria-Mendoza, A., Valladales-Restrepo, L. F., & Machado-Alba, J. E.
- ORCID
- Venue
- Drugs - Real World Outcomes
- Published
- 2025-10-03
- Volume
- 12
- Issue
- 4
- Pages
- 615-622
- ISSN
- 2198-9788 (ISSN-L)
- 2199-1154
- PMC
- PMC12635016
- OpenAlex
- W4414773967
- Cited by
- 2
- References
- 25
- Citations by year
- 2026: 2
- FWCI
- 1.36
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by-nc
- creativecommons.org/licenses/by-nc/4.0 (tdm)
- creativecommons.org/licenses/by-nc/4.0 (vor)
- Locations
- Drugs - Real World Outcomes (publishedVersion, cc-by-nc)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Family Practice › Medication Adherence and Compliance
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Keywords
- semaglutide, treatment persistence, type 2 diabetes, obesity, GLP-1 receptor agonists, weight loss, antidiabetic drugs, metformin, SGLT2 inhibitors, insulin, drug tolerability, access to medicines, Colombia
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Persistence of Weekly Injectable Semaglutide Use in Patients with Diabetes Mellitus and Obesity: A Retrospective Follow-Up in Colombia. https://app.cochat.ai/papers/10.1007/s40801-025-00518-6
- The paper
- Machado-Duque, M. E., Gaviria-Mendoza, A., Valladales-Restrepo, L. F., & Machado-Alba, J. E. (2025). Persistence of Weekly Injectable Semaglutide Use in Patients with Diabetes Mellitus and Obesity: A Retrospective Follow-Up in Colombia. Drugs - Real World Outcomes. https://doi.org/10.1007/s40801-025-00518-6
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.

